Paul Feuerstadt, Ari L. Bunim, Heriberto Garcia, Jordan J. Karlitz, Hatef Massoumi, Amar J. Thosani, Andrew Pellecchia, Allan W. Wolkoff, Paul J. Gaglio, John F. Reinus – 26 March 2010 – Randomized controlled trials of hepatitis C virus (HCV) therapy with pegylated interferon and ribavirin have demonstrated sustained viral response rates (SVRs) of 54%‐63% (efficacy). Treatment results in clinical practice (effectiveness) may not be equivalent.

Heping Yang, Kwangsuk Ko, Meng Xia, Tony W.H. Li, Pilsoo Oh, Jiaping Li, Shelly C. Lu – 26 March 2010 – We previously showed that hepatic expression of glutathione (GSH) synthetic enzymes and GSH levels fell 2 weeks after bile duct ligation (BDL) in mice. This correlated with a switch in nuclear anti‐oxidant response element (ARE) binding activity from nuclear factor erythroid 2–related factor 2 (Nrf2) to c–avian musculoaponeurotic fibrosarcoma (c‐Maf)/V‐maf musculoaponeurotic fibrosarcoma oncogene homolog G (MafG).

Nicole K. Paulk, Karsten Wursthorn, Zhongya Wang, Milton J. Finegold, Mark A. Kay, Markus Grompe – 26 March 2010 – Adeno‐associated virus (AAV) vectors are ideal for performing gene repair due to their ability to target multiple different genomic loci, low immunogenicity, capability to achieve targeted and stable expression through integration, and low mutagenic and oncogenic potential. However, many handicaps to gene repair therapy remain. Most notable is the low frequency of correction in vivo. To date, this frequency is too low to be of therapeutic value for any disease.

Anna S. Lok – 26 March 2010

Silvia Fargion, Luca Valenti, Anna Ludovica Fracanzani – 26 March 2010

Jesper B. Andersen, Roberto Loi, Andrea Perra, Valentina M. Factor, Giovanna M. Ledda‐Columbano, Amedeo Columbano, Snorri S. Thorgeirsson – 26 March 2010 – Human hepatocellular carcinoma (HCC) is a heterogeneous disease of distinct clinical subgroups. A principal source of tumor heterogeneity may be cell type of origin, which in liver includes hepatocyte or adult stem/progenitor cells. To address this issue, we investigated the molecular mechanisms underlying the fate of the enzyme‐altered preneoplastic lesions in the resistant hepatocyte (RH) model.

Dong‐Jiang Tang, Sui‐Sui Dong, Ning‐Fang Ma, Dan Xie, Leilei Chen, Li Fu, Sze Hang Lau, Yan Li, Yan Li, Xin‐Yuan Guan – 26 March 2010 – A high incidence of tumor recurrence and metastasis has been reported in hepatocellular carcinoma (HCC) patients; however, the underlying molecular mechanisms are largely unknown. In the present study a novel metastasis‐related gene, eukaryotic initiation factor 5A2 (EIF5A2), was characterized for its role in HCC metastasis and underlying molecular mechanisms.

Xuequn Zhang, Juntao Yang, Yuanbiao Guo, Hua Ye, Chaohui Yu, Chengfu Xu, Lei Xu, Songfeng Wu, Wei Sun, Hangdong Wei, Xue Gao, Yunping Zhu, Xiaohong Qian, Ying Jiang, Youming Li, Fuchu He – 26 March 2010 – Nonalcoholic fatty liver disease (NAFLD) has emerged as a common public health problem that can progress to end‐stage liver disease. A high‐fat diet (HFD) may promote the development of NAFLD through a mechanism that is poorly understood. We adopted a proteomic approach to examine the effect of HFD on the liver proteome during the progression of NAFLD.

P. Thomas Cherian, Bassem Hegab, Simon P. Oliff, Stephen J. Wigmore – 26 March 2010 – In the presence of anatomical variants such as an accessory or replaced (A/R) right hepatic artery (RHA), a conflict of interest can arise during organ retrieval between liver and pancreatic teams. This angiographic study examines the anatomy of the inferior pancreaticoduodenal artery (IPDA), its relation to the A/R RHA, and the implications for the use of livers and pancreases from multiorgan donors.

I‐Chin Wu, Ching‐Lung Lai, Steven‐Huy Bui Han, Kwang‐Hyup Han, Stuart C. Gordon, You‐Chen Chao, Chee‐Kiat Tan, William Sievert, Tawesak Tanwandee, Dong Xu, Boon‐Leong Neo, Ting‐Tsung Chang – 26 March 2010 – Current guidelines for management of chronic hepatitis B recommend treatment for patients presenting with elevated hepatitis B virus (HBV) DNA and alanine aminotransferase (ALT) >2 × upper limit of normal (ULN) or histological evidence of liver disease.